Background: Adiponectin, a circulating adipocyte-derived protein has insulinsensitizing, anti-inflammatory, anti-atherogenic, and cardiomyocyte-protective properties in animal models. However, the systemic effects of adiponectin in humans are unknown.
INTRODUCTION
The recognition that adipose tissue is an endocrine organ raised new prospects for discovering adipose-derived products that could be valuable drug targets for the treatment and prevention of cardio-metabolic diseases. In this context, adiponectin, a 30KDa protein largely produced by mature adipocytes, has been attracting widespread attention due to insulin-sensitizing, anti-inflammatory, antiatherogenic, and cardiomyocyte-protective properties demonstrated in animal models (1).
However, human studies have yielded a far more complicated picture. Unlike most other adipokines, circulating adiponectin concentration is higher with lower adiposity (2). In prospective observational studies in humans using multivariable regression, higher circulating adiponectin is associated with lower risk of type 2 diabetes (3), hepatic dysfunction (4), and metabolic syndrome (5), but higher mortality in patients with kidney disease, heart failure, previous cardiovascular disease or general elderly cohorts (6-9); this different direction of effect between risk of incident disease and mortality among high risk groups has been called "the adiponectin paradox" (10).
Given the complex metabolic derangements that might participate in and compensatory changes that might occur in response to human diseases, the association between adiponectin concentration and cardio-metabolic biomarkers and disease end-points might be explained by reverse causality (where disease status could alter adiponectin concentration) or residual confounding (where adiponectin could be a marker of another causal factor, such as adiposity or insulin resistance) (11) . Classical multivariable regression studies cannot distinguish causal from noncausal associations, and randomized controlled trials (RCTs) specifically targeting adiponectin are not possible in the absence of a specific therapeutic targeting adiponectin concentration or function.
Mendelian randomization uses genetic variants (mostly single nucleotide polymorphisms (SNPs)) that are robustly related to the risk factor of interest as tools to assess its role in causing disease (12) . The random allocation of parental alleles at meiosis should theoretically reduce confounding in genetic association studies and this has been shown to be the case (13); the unidirectional flow of biological information from genetic variant to phenotypes avoids reverse causality. Mendelian randomization has been used in clinical research to investigate potential etiological mechanisms, such as the causal effects of low density lipoprotein cholesterol (LDL-c) (14) , systolic blood pressure (SBP) (14) and C reactive protein (15) on coronary heart disease (CHD), validate and prioritize novel drug targets, such as interleukin-6 receptor (16), and increase understanding of current therapies, for example statins (17) .
Previous Mendelian randomization studies indicate that circulating adiponectin is a consequence of low insulin sensitivity (18), but whether adiponectin concentration is also a cause of insulin sensitivity is uncertain (18) (19) (20) . Using Mendelian randomization in a study of 63,746 CHD cases and 130,681 controls we have recently shown that adiponectin may not be causally related to CHD (21) .
Whilst multivariable analyses show higher adiponectin concentration is associated with lower glycated haemoglobin, insulin, triglycerides and higher high density lipoprotein-cholesterol (HDL-c), using Mendelian randomization, we found little evidence these were causal (21) . Whether adiponectin is associated with systemic metabolic profile, and, if it is, what aspects of these associations are causal is unknown. A broader interrogation of the metabolic effects of adiponectin through high-throughput profiling of metabolic status could provide valuable insights into whether adiponectin is a non-causal biomarker or causally important in the pathophysiology of some human diseases (22) .
We combined genotype, adiponectin and metabolomics profile data from six longitudinal studies and one genome-wide association consortium with the aim of (i) defining the metabolic effects of blood adiponectin concentration and (ii) investigating whether variation in adiponectin concentration is causally related to the systemic metabolic profile.
METHODS

Study Populations
The metabolic profile associated with blood adiponectin concentration was examined from seven data sources: the 1982 Pelotas Birth Cohort (PEL82), including adults aged 30 years old born in the city of Pelotas, Brazil, in 1982 (23, 24) ; the British Women's Heart and Health Study (BWHHS), including UK women aged 60-79 years old at recruitment in 2000 (25) ; the Whitehall II Study (WHII), including UK government workers aged 45-69 years at phase 5 clinical assessment in 1997-1999 (26) ; the Caerphilly Prospective Study (CaPS), including men aged 52-72 years at phase III in 1989-1993 (27) ; a case-control study nested in The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), including UK postmenopausal women aged 50-74 years at recruitment in 2001-2005 (28) ; the cohort of mothers from The Avon Longitudinal Study of Children and Parents (ALSPAC-M), including UK women aged 34-63 years old at clinical assessment in 2009-2011 (29) ; and a metabolomics genome-wide association consortium (Metabolomics consortium), including European adults with mean age of 45 years old from 14 cohorts (30). Individual level data was available to investigators from PEL82, BWHHS, WHII, CaPS, UKCTOCS and ALSPAC-M and summary level data is publicly available from the Metabolomics consortium (URL:
http://www.computationalmedicine.fi/data/NMR_GWAS/). All study participants provided written informed consent, and study protocols were approved by the local ethics committees (ethical approval for ALSPAC was also obtained from the ALSPAC Ethics and Law Committee). Studies' characteristics are summarized on Table 1 . We examined (possibly causal) associations of adiponectin with systemic metabolic profiles using two approaches -conventional multivariable regression and Mendelian randomization analyses. Studies must have both adiponectin and measures of some of the outcomes (but do not need genetic data) to contribute to multivariable regression analyses, and must have relevant genetic variants and outcomes (but do not need adiponectin concentration data) to contribute to Mendelian randomization analyses. Figure 1 shows how the different data sources contributed to the two approaches.
Metabolite Quantification
A high-throughput serum nuclear magnetic resonance (NMR) spectroscopy platform was utilized to quantify up to 150 metabolic measures and 83 derived measures (ratios) in each study. This NMR platform has been used in several other studies (22, 31, 32) and methodological details have been described elsewhere (33, 34) . 66 out of 150 metabolic measures were selected for this study aimed at broadly representing the systemic metabolite profile, as previously reported by Wurtz et al (35) , including: lipoprotein traits (lipid content, particle size, and apolipoproteins), free fatty acids, amino acids, glycolysis-related metabolites, ketone bodies, fluid balance (albumin and creatinine), and inflammatory markers (glycoprotein acetyls). The remaining 84 metabolic measures from the NMR platform are related to other lipid fractions (esterified and free cholesterol, total cholesterol, triglycerides, and phospholipids) and particle concentration from 14 lipoprotein subclasses and are not presented in this study. Instead, we present the total lipid content of each of the 14 lipoprotein subclasses, which is highly correlated to their respective lipid fractions and particle concentration and comprehensively represents the plasma lipid partitioning across lipoproteins. Eight additional measures, not obtained from the NMR platform, were also included: C-reactive protein (CRP), interleukin (IL)-6, fibrinogen, blood viscosity, insulin, glycated haemoglobin (Hb A1c ), and systolic (SBP) and diastolic blood pressure (DBP). PEL82 did not have data on metabolic measures from NMR platform and contributed data to analyses of conventional lipid risk factors (total cholesterol, HDL-c, LDL-c, and triglycerides (TG)), and some of the additional measures described (CRP, Hb A1c , SBP, DBP Further details can be found in the consortium publication (30).
Other covariates
Anthropometric variables (weight and height) were measured in each study using standard procedures and body mass index (BMI) was calculated as weight (kg)/height (m) 2 . Demographic and smoking status information were obtained through questionnaires.
Data analysis
Prior to analyses, metabolic measures were adjusted for age, sex, and, if applicable, place of recruitment (BWHHS and UKCTOCS) or principal components of genomic ancestry (PEL82 and some studies contributing to Metabolomics consortium) and the resulting residuals were transformed to normal distribution by inverse rank-based normal transformation. Pregnant women from PEL82 (n = 73) and ALSPAC-M (n = 12) were excluded. As the 74 analysed metabolites are highly correlated, we adopted a similar strategy to the Metabolomics consortium (30) to correct for multiple testing by estimating the number of independent tests as the number of principal components that explained over 95% of variance in metabolites concentration using data from the two studies (BWHHS and WHII) with the largest available number of metabolites (n = 27 principal components in both studies). As a result, for both multivariable and Mendelian randomization analyses, we corrected for multiple testing using the Bonferroni method considering 27 independent tests (p = 0.05 ÷ 27 ≈ 0.0019).
Multivariable regression analysis
The conventional multivariable regression association of adiponectin with individual metabolites was estimated using a two-stage individual participant metaanalysis. In the first stage, linear regression models were fitted for each study. In the second stage, study-specific estimates were meta-analysed using DerSimonian & Laird random effect model (40). Heterogeneity across studies was assessed using I 2 (as a measure of the relative size of between-study variation and within-study error) (41). Three types of subgroup analyses were conducted: sex-stratified analysis, analysis excluding individuals with high risk of cardiometabolic disease (those that had experienced coronary artery disease or stroke or those older than 65 years old) and analysis restricted to European studies (excluding PEL82).
Genetic analyses
Selection of genetic variants. 
RESULTS
The study included a median sample size of 3,006 adults in the multivariable analysis (range: 2,497-5,906) and a median sample size of 23,884 adults in the Mendelian randomization analysis (range: 4,645-38,058). Characteristics of participants from each contributing study are listed in Table 2 .
Adiponectin and the Systemic Metabolic Profile
In the multivariable analysis, adiponectin was associated with 59 out of 74 (80%) metabolites at nominal level (p < 0.05) and 49 out of 74 (66%) after correcting for multiple testing (p < 0.0019). Overall, higher circulating adiponectin was associated with a healthier systemic metabolite profile. Blood adiponectin concentration was strongly related to multiple lipoprotein traits. With higher adiponectin concentration, lipid concentration was lower in VLDL subclasses and higher in HDL subclasses, except for small HDL. There was no strong evidence of circulating adiponectin associating with total lipid content in LDL subclasses or in IDL, although adiponectin concentration was inversely associated with LDL-cholesterol.
Higher adiponectin was associated with lower concentration of cholesterol and triglycerides, lower mean particle diameter in VLDL and higher cholesterol concentration and mean particle diameter in HDL. Higher adiponectin concentration was also associated with higher concentration of apolipoprotein (Apo)-AI and phospholipids and lower concentration of triglycerides and diglycerides (Figure 2) .
Higher circulating adiponectin was also associated with healthier glycemic status (lower glucose and insulin concentration), lower blood concentration of glycolysis-related metabolites (lactate and pyruvate), saturated fatty acids, systemic inflammatory markers (C-reactive protein, fibrinogen, interleukin-6, glycoprotein acetyls and blood viscosity), systolic blood pressure, creatinine, and higher ketone bodies (acetoacetate). In addition, higher adiponectin concentration was associated with lower concentrations of free branched chain amino acids (isoleucine, leucine, and valine), aromatic amino acids (phenylalanine and tyrosine), and alanine and higher concentration of glutamine (Figure 3) .
In the multivariable analyses, evidence of heterogeneity in pooled estimates across studies was substantial (I 2 = 50%-75%) for 12 and very high (I 2 > 75%) for 15 metabolic measures (Figure 2 and 3 
Causal effects of adiponectin on the Systemic Metabolic Profile
Characteristics of the four SNPs (rs6810075, rs16861209, rs17366568 and rs3774261) used in Mendelian randomization and their association with adiponectin concentration are shown in Table 3 . Overall, SNPs effect allele frequency was similar across studies. Two SNPs had lower allele frequency in the Metabolomics consortium (rs6810075: 51% vs. 65-69% in other studies; rs16861209: 5% vs. 9-11% in other studies) and one SNP had a higher frequency in PEL82 compared to other studies (rs3774261: 49% vs. 38-39% in other studies) ( Table 3) . As expected, the selected SNPs were not associated with classical confounders overall ( Supplementary table 3) .
Findings from Mendelian randomization analysis were largely inconsistent with results from multivariable analysis. Firstly, there was no evidence that adiponectin influenced HDL and VLDL traits (Figure 2) . Secondly, genetically-increased adiponectin levels were not associated with glycemic traits, free amino acids, and glycolysis-related metabolites (Figure 3) . Results were less conclusive for some inflammatory markers (IL-6 and fibrinogen) (Figure 3) . Thirdly, there was strong statistical evidence that associations from multivariable and Mendelian randomization analyses were inconsistent with each other (Figure 2 and Figure 3 ) and the overall correlation between multivariable and Mendelian randomization estimates was very low (r = 0.10) (Figure 4) . Finally, in the Mendelian randomization analysis, adiponectin was not associated with any of the metabolic analyses at either p < 0.05 or p < 0.00068.
In the Mendelian randomization analyses, evidence of heterogeneity in pooled estimates across studies were substantial (I 2 = 50%-75%) for 14 and very high (I 2 > 75%) for 3 metabolic measures, suggesting lower heterogeneity in models from genetic analysis than from the multivariable analyses (Figure 2 and 3 and Supplementary table 2 ). This did not seem to be driven by sex differences (Supplementary figures 1 to 4) , geographic location/ethnicity (Supplementary figures 5 and 6), or high risk of disease (Supplementary figures 7 and 8 ).
DISCUSSION
In up to 5,906 adults we found using multivariable regression analyses that circulating adiponectin was associated with a pattern of systemic metabolites levels associated with good health. Higher blood adiponectin concentration was associated with higher HDL lipids and lower VLDL lipids, glycaemia, and branched-chain amino acids levels. However, when we used genetic variants in the ADIPOQ locus to test the causal effect of adiponectin on systemic metabolic profiles amongst up to 38,058 adults, we found little evidence that the associations were causal.
Despite the evidence of shared genetic architecture between adiponectin concentration and cardio-metabolic diseases (42), previous Mendelian randomization studies have cast doubt on the causal role of blood adiponectin levels in the risk of type 2 diabetes (18) and coronary heart disease (21). In addition, there seems to be no consistent evidence that circulating adiponectin causally affects traditional cardiovascular risk factors, such as HDL-c, LDL-c, triglycerides, and fasting glucose in the population (18). We have added importantly to those previous studies and explored effects on systemic metabolic profiles. Taken together, this and previous
Mendelian randomization studies suggest that the association between circulating adiponectin and metabolic biomarkers and cardio-metabolic diseases is likely to be explained by shared factors (confounding) rather than by a direct role of adiponectin on metabolism and downstream cardio-metabolic disease. These results are in contrast to findings from animal models pointing to insulin-sensitizing, and antiatherogenic actions of adiponectin (1).
Circulating adiponectin is known to be substantially reduced among obese individuals, particularly in the presence of central fat accumulation (46). A recent Mendelian randomization study examining the causal metabolic effects of BMI demonstrated that lower BMI was related to favorable lipoprotein subclass profile and lower concentration of branched-chain amino acids, inflammatory markers, and insulin (35), which is remarkably similar to our results from the conventional multivariable analysis. In addition, numerous studies have shown that adiponectin production is supressed by insulin action in humans, which seems to be at least partly attributed to regulation at the transcriptional level (11, 47). As an example, elevated circulating adiponectin is found in contexts of both primary deficiency of insulin (type 1 diabetes) (48) and global insulin resistance due to genetic or acquired defects in the insulin receptor (49). Evidence from animal models has raised the possibility of a bidirectional relationship between adiponectin and insulin concentration (50). Early Mendelian randomization studies did indicate that adiponectin could mitigate insulin resistance (19, 20) ; however, these results could not be replicated in a larger Mendelian randomization study (18), as well as in our study presented here. The well-known metabolic effects of adiposity and insulin on circulating adiponectin concentration reinforce that the clustering of adiponectin and several traditional and novel biomarkers is likely to result from confounding due to increasing adiposity and disruption of insulin action.
Strengths of our study include detailed metabolic profile in several longitudinal studies, which enabled us to characterize the metabolic profile of high adiponectin concentration beyond traditional biomarkers, as well as the use of Mendelian randomization to disentangle the causal effect of adiponectin on the metabolism.
Mendelian randomization analysis can reliably test for the presence of a causal
relation under the three assumptions of an instrumental variable that the genetic variants are robustly associated with the risk factor of interest (adiponectin) (1), should only affect the outcome (metabolites) through the exposure (2), and are not associated with exposure-outcome confounders (3) (51). To ensure that IV assumptions were met, or were at least plausible, we only used SNPs strongly and specifically (within ADIPOQ gene) related to adiponectin concentration as instrumental variables and we adjusted for population structure in models using data from PEL82 to avoid confounding by population stratification. One of the limitations of our study was the limited power in subgroup analyses including only individual-level data (sex-and risk-stratified analyses), which limited our investigation of potential sources of heterogeneity. Another limitation was the absence of data on highmolecular weight adiponectin, which is believed to account for most of the adiponectin biological effects in experimental settings. However, most human (and many animal model) studies have not used high-molecular weight adiponectin, and we found the same multivariable observational associations as in previous studies.
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SUPPLEMENTARY METHODS
Mendelian randomization analyses
The two-sample Mendelian randomization estimates and respective standard errors were obtained using the inverse variance-weighted (IVW) method with the following formulas: To increase precision and avoid bias due to statistical overfitting, estimates for X k were obtained from ADIPOGen consortium dataset (42). Prior to analysis, estimates from ADIPOGen consortium were standardized (converted from log adiponectin to standardized log adiponectin units) using individual level data from PEL82 with a similar adiponectin distribution (adiponectin concentration in ADIPOGen consortium: mean = 9.8 µg/ml (standard deviation = 5.6); adiponectin concentration in 1982 Pelotas Birth Cohort: mean = 9.3 µg/ml (standard deviation = 5.7)). Estimates for Y k were derived from each study using linear regression models considering an additive model for SNP alleles.
Comparison between multivariable and Mendelian randomization analyses
Results from conventional multivariable and Mendelian randomization analyses were compared using the Z-test:
Where β obs represents estimates from conventional observational analysis (with respective standard error, SE obs ) and β MR represents estimates from Mendelian randomization analysis (with respective standard error, SE MR ).
Proportion of variance in adiponectin concentration explained by genetic instruments
In order to estimate the strength of our genetic instruments, we estimated the phenotypic variance explained by a given SNP (R 2 ) for adiponectin concentration.
We used ADIPOGen summary data to approximate R 2 for a given SNP based on the effect estimate for its association with the trait of interest (beta or ߚ መ ), respective standard error (‫݁ݏ‬ሺߚ መ ሻ ), minor allele frequency (MAF), and sample size (N). The following formula was used as previously described by Shim et al., 2015 (52) : Supplementary figure 1. Association of lipoprotein traits with blood adiponectin levels from observational and Mendelian randomization (MR) analysis among women.
Values are expressed as units of standardized log metabolite concentration (and 95% CI) per 1 unit increment of standardized log adiponectin levels. P-values for the association between adiponectin and metabolites are indicated by three asterisks ("***") if lower than Bonferroni-adjusted threshold (Pvalue < 0.00068). Heterogeneity was considered substantial if I 2 = 50-75% ("+") or very high if I 2 > 75% ("++"). P-values for the comparison between multivariable and Mendelian randomization estimates are displayed in the column "MR vs MV (P-value)". Supplementary figure 2. Association of multiple metabolic measures with blood adiponectin levels from observational and Mendelian randomization analysis among women.
Values are expressed as units of standardized log metabolite concentration (and 95% CI) per 1 unit increment of standardized log adiponectin levels. P-values for the association between adiponectin and metabolites are indicated by three asterisks ("***") if lower than Bonferroni-adjusted threshold (P-value < 0.00068). Heterogeneity was considered substantial if I 2 = 50-75% ("+") or very high if I 2 > 75% ("++" Supplementary figure 3 . Association of lipoprotein traits with blood adiponectin levels from observational and Mendelian randomization (MR) analysis among men.
Values are expressed as units of standardized log metabolite concentration (and 95% CI) per 1 unit increment of standardized log adiponectin levels. P-values for the association between adiponectin and metabolites are indicated by three asterisks ("***") if lower than Bonferroni-adjusted threshold (Pvalue < 0.00068). Heterogeneity was considered substantial if I 2 = 50-75% ("+"), very high if I 2 > 75% ("++") or not applicable ("NA") when only one study contributed to the estimate. P-values for the comparison between multivariable and Mendelian randomization estimates are displayed in the column "MR vs MV (P-value)". Metabolic measures were adjusted for age, sex, and, if applicable, place of recruitment (BWHHS and UKCTOCS) or principal components of genomic ancestry (PEL82 and some studies contributing to Metabolomics consortium) and the resulting residuals were Values are expressed as units of standardized log metabolite concentration (and 95% CI) per 1 unit increment of standardized log adiponectin levels. P-values for the association between adiponectin and metabolites are indicated by three asterisks ("***") if lower than Bonferroni-adjusted threshold (P-value < 0.00068). Heterogeneity was considered substantial if I 2 = 50-75% ("+") or very high if I 2 > 75% ("++") or not applicable ("NA") when only one study contributed to the estimate. P-values for the comparison between multivariable and Mendelian randomization estimates are displayed in the column "MR vs MV (P-value)". Metabolic measures were adjusted for age, sex, and, if applicable, place of recruitment (BWHHS and UKCTOCS) or principal components of genomic ancestry (PEL82 and some studies contributing to Metabolomics consortium) and the resulting residuals were transformed to normal distribution by inverse rank-based normal transformation. Values are expressed as units of standardized log metabolite concentration (and 95% CI) per 1 unit increment of standardized log adiponectin levels. P-values for the association between adiponectin and metabolites are indicated by three asterisks ("***") if lower than Bonferroni-adjusted threshold (Pvalue < 0.00068). Heterogeneity was considered substantial if I 2 = 50-75% ("+") or very high if I 2 > 75% ("++" Supplementary figure 6. Association of multiple metabolic measures with blood adiponectin levels from observational and Mendelian randomization analysis restricted to individuals of European ancestry.
Values are expressed as units of standardized log metabolite concentration (and 95% CI) per 1 unit increment of standardized log adiponectin levels. P-values for the association between adiponectin and metabolites are indicated by three asterisks ("***") if lower than Bonferroni-adjusted threshold (P-value < 0.00068). Heterogeneity was considered substantial if I 2 = 50-75% ("+") or very high if I 2 > 75% ("++" Supplementary figure 7 . Association of lipoprotein traits with blood adiponectin levels from observational and Mendelian randomization (MR) analysis among younger individuals (< 65 years old) free from cardiovascular disease.
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